BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Fetting J. Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood. Clin Cancer Res. 2012;18:3462-3469. [PMID: 22421194 DOI: 10.1158/1078-0432.ccr-11-2696] [Cited by in Crossref: 235] [Cited by in F6Publishing: 113] [Article Influence: 23.5] [Reference Citation Analysis]
Number Citing Articles
1 Goldstein A, Toro PV, Lee J, Silberstein JL, Nakazawa M, Waters I, Cravero K, Chu D, Cochran RL, Kim M, Shinn D, Torquato S, Hughes RM, Pallavajjala A, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Trock BJ, Eisenberger MA, Antonarakis ES, Park BH, Hurley PJ. Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget. 2017;8:15651-15662. [PMID: 28152506 DOI: 10.18632/oncotarget.14926] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
2 Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531-548. [PMID: 28252003 DOI: 10.1038/nrclinonc.2017.14] [Cited by in Crossref: 770] [Cited by in F6Publishing: 743] [Article Influence: 154.0] [Reference Citation Analysis]
3 Möhrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res 2018;24:181-8. [PMID: 29051321 DOI: 10.1158/1078-0432.CCR-17-2007] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 12.2] [Reference Citation Analysis]
4 Hu ZY, Xie N, Tian C, Yang X, Liu L, Li J, Xiao H, Wu H, Lu J, Gao J, Hu X, Cao M, Shui Z, Xiao M, Tang Y, He Q, Chang L, Xia X, Yi X, Liao Q, Ouyang Q. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance. EBioMedicine 2018;32:111-8. [PMID: 29807833 DOI: 10.1016/j.ebiom.2018.05.015] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
5 Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087. [PMID: 30923679 DOI: 10.1016/j.bdq.2019.100087] [Cited by in Crossref: 142] [Cited by in F6Publishing: 124] [Article Influence: 47.3] [Reference Citation Analysis]
6 Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ. Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther 2014;13:3210-8. [PMID: 25319388 DOI: 10.1158/1535-7163.MCT-14-0349] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
7 Rapisuwon S, Vietsch EE, Wellstein A. Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J. 2016;14:211-222. [PMID: 27358717 DOI: 10.1016/j.csbj.2016.05.004] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 13.8] [Reference Citation Analysis]
8 Shang M, Chang C, Pei Y, Guan Y, Chang J, Li H. Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer. J Cancer 2018;9:4627-34. [PMID: 30588246 DOI: 10.7150/jca.28458] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
9 Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res 2017;23:3657-66. [PMID: 28096270 DOI: 10.1158/1078-0432.CCR-16-2592] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 6.6] [Reference Citation Analysis]
10 Parsons HA, Beaver JA, Cimino-Mathews A, Ali SM, Axilbund J, Chu D, Connolly RM, Cochran RL, Croessmann S, Clark TA, Gocke CD, Jeter SC, Kennedy MR, Lauring J, Lee J, Lipson D, Miller VA, Otto GA, Rosner GL, Ross JS, Slater S, Stephens PJ, VanDenBerg DA, Wolff AC, Young LE, Zabransky DJ, Zhang Z, Zorzi J, Stearns V, Park BH. Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 2017;23:379-86. [PMID: 27489289 DOI: 10.1158/1078-0432.CCR-16-1543] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
11 García-Saenz JA, Ayllón P, Laig M, Acosta-Eyzaguirre D, García-Esquinas M, Montes M, Sanz J, Barquín M, Moreno F, Garcia-Barberan V, Díaz-Rubio E, Caldes T, Romero A. Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. BMC Cancer 2017;17:210. [PMID: 28330468 DOI: 10.1186/s12885-017-3185-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
12 Peeters DJ, De Laere B, Van den Eynden GG, Van Laere SJ, Rothé F, Ignatiadis M, Sieuwerts AM, Lambrechts D, Rutten A, van Dam PA, Pauwels P, Peeters M, Vermeulen PB, Dirix LY. Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer 2013;108:1358-67. [PMID: 23470469 DOI: 10.1038/bjc.2013.92] [Cited by in Crossref: 116] [Cited by in F6Publishing: 107] [Article Influence: 12.9] [Reference Citation Analysis]
13 Mo H, Wang X, Ma F, Qian Z, Sun X, Yi Z, Guan X, Li L, Liu B, Xu B. Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer. Breast 2020;53:111-8. [PMID: 32738630 DOI: 10.1016/j.breast.2020.07.004] [Reference Citation Analysis]
14 Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res 2017;23:5648-56. [PMID: 28536309 DOI: 10.1158/1078-0432.CCR-17-0291] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
15 Kaklamani VG, Richardson AL, Arteaga CL. Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer. Oncologist 2019;24:305-12. [PMID: 30651399 DOI: 10.1634/theoncologist.2018-0314] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Mathé E, Hays JL, Stover DG, Chen JL. The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources. Yearb Med Inform 2018;27:211-22. [PMID: 30157526 DOI: 10.1055/s-0038-1667085] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
17 Zhou Y, Xu Y, Gong Y, Zhang Y, Lu Y, Wang C, Yao R, Li P, Guan Y, Wang J, Xia X, Yang L, Yi X, Sun Q. Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer. Mol Oncol 2019;13:1033-46. [PMID: 30672098 DOI: 10.1002/1878-0261.12456] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
18 Peeters M, Karthaus M, Rivera F, Terwey JH, Douillard JY. Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status. Drugs 2015;75:731-48. [PMID: 25895463 DOI: 10.1007/s40265-015-0386-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
19 Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10:472-484. [PMID: 23836314 DOI: 10.1038/nrclinonc.2013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Schneck H, Blassl C, Meier-Stiegen F, Neves RP, Janni W, Fehm T, Neubauer H. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2013;7:976-986. [PMID: 23895914 DOI: 10.1016/j.molonc.2013.07.007] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
21 Corné J, Le Du F, Quillien V, Godey F, Robert L, Bourien H, Brunot A, Crouzet L, Perrin C, Lefeuvre-Plesse C, Diéras V, De la Motte Rouge T. Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients. Sci Rep 2021;11:17316. [PMID: 34453076 DOI: 10.1038/s41598-021-96644-6] [Reference Citation Analysis]
22 Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky DJ, Wong HY, Toro PV, Cidado J, Blair BG, Chu D, Burns T, Higgins MJ, Stearns V, Jacobs L, Habibi M, Lange J, Hurley PJ, Lauring J, VanDenBerg D, Kessler J, Jeter S, Samuels ML, Maar D, Cope L, Cimino-Mathews A, Argani P, Wolff AC, Park BH. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res. 2014;20:2643-2650. [PMID: 24504125 DOI: 10.1158/1078-0432.ccr-13-2933] [Cited by in Crossref: 249] [Cited by in F6Publishing: 125] [Article Influence: 31.1] [Reference Citation Analysis]
23 Aarthy R, Mani S, Velusami S, Sundarsingh S, Rajkumar T. Role of Circulating Cell-Free DNA in Cancers. Mol Diagn Ther 2015;19:339-50. [PMID: 26400814 DOI: 10.1007/s40291-015-0167-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
24 Richardson AL, Iglehart JD. BEAMing up personalized medicine: mutation detection in blood. Clin Cancer Res 2012;18:3209-11. [PMID: 22550168 DOI: 10.1158/1078-0432.CCR-12-0871] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
25 De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, Seoane J. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 2013;10:377-89. [PMID: 23712187 DOI: 10.1038/nrclinonc.2013.80] [Cited by in Crossref: 125] [Cited by in F6Publishing: 116] [Article Influence: 13.9] [Reference Citation Analysis]
26 Le Du F, Ueno NT, Gonzalez-Angulo AM. Breast Cancer Biomarkers: Utility in Clinical Practice. Curr Breast Cancer Rep 2013;5. [PMID: 24416469 DOI: 10.1007/s12609-013-0125-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
27 Lin Z, Neiswender J, Fang B, Ma X, Zhang J, Hu X. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis. Oncotarget 2017;8:26625-36. [PMID: 28460452 DOI: 10.18632/oncotarget.15775] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
28 Dawson SJ. Characterizing the Cancer Genome in Blood. Cold Spring Harb Perspect Med 2019;9:a026880. [PMID: 29844219 DOI: 10.1101/cshperspect.a026880] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
29 Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res 2017;23:5101-11. [PMID: 28539465 DOI: 10.1158/1078-0432.CCR-16-2497] [Cited by in Crossref: 84] [Cited by in F6Publishing: 58] [Article Influence: 16.8] [Reference Citation Analysis]
30 Rudolph M, Anzeneder T, Schulz A, Beckmann G, Byrne AT, Jeffers M, Pena C, Politz O, Köchert K, Vonk R, Reischl J. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer 2016;16:622. [PMID: 27515171 DOI: 10.1186/s12885-016-2626-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
31 Olmedillas-lópez S, García-arranz M, García-olmo D. Current and Emerging Applications of Droplet Digital PCR in Oncology. Mol Diagn Ther 2017;21:493-510. [DOI: 10.1007/s40291-017-0278-8] [Cited by in Crossref: 80] [Cited by in F6Publishing: 71] [Article Influence: 16.0] [Reference Citation Analysis]
32 Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB, Johnson BE. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J Natl Cancer Inst. 2014;106. [PMID: 25106647 DOI: 10.1093/jnci/dju214] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
33 Karakas B, Qubbaj W, Al-Hassan S, Coskun S. Noninvasive Digital Detection of Fetal DNA in Plasma of 4-Week-Pregnant Women following In Vitro Fertilization and Embryo Transfer. PLoS One 2015;10:e0126501. [PMID: 25970589 DOI: 10.1371/journal.pone.0126501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Cheung AH, Chow C, To KF. Latest development of liquid biopsy. J Thorac Dis 2018;10:S1645-51. [PMID: 30034830 DOI: 10.21037/jtd.2018.04.68] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
35 Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. Prostate 2019;79:701-8. [PMID: 30865311 DOI: 10.1002/pros.23778] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
36 Pesapane F, Suter MB, Rotili A, Penco S, Nigro O, Cremonesi M, Bellomi M, Jereczek-Fossa BA, Pinotti G, Cassano E. Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation? Med Oncol 2020;37:29. [PMID: 32180032 DOI: 10.1007/s12032-020-01353-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
37 Kodahl AR, Ehmsen S, Pallisgaard N, Jylling AMB, Jensen JD, Laenkholm AV, Knoop AS, Ditzel HJ. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer. Mol Oncol 2018;12:925-35. [PMID: 29689598 DOI: 10.1002/1878-0261.12305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 1] [Article Influence: 7.8] [Reference Citation Analysis]
38 Tu M, Chia D, Wei F, Wong D. Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB). Analyst 2016;141:393-402. [PMID: 26645892 DOI: 10.1039/c5an01863c] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
39 Koba H, Kimura H, Yoneda T, Sone T, Ohkura N, Hara J, Hosomichi K, Tajima A, Kasahara K. Molecular features of tumor-derived genetic alterations in circulating cell-free DNA in virtue of autopsy analysis. Sci Rep 2021;11:8398. [PMID: 33863951 DOI: 10.1038/s41598-021-87094-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Kosovec JE, Zaidi AH, Pounardjian TS, Jobe BA. The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy. Front Oncol 2018;8:610. [PMID: 30619750 DOI: 10.3389/fonc.2018.00610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
41 Qin Z, Ljubimov VA, Zhou C, Tong Y, Liang J. Cell-free circulating tumor DNA in cancer. Chin J Cancer 2016;35:36. [PMID: 27056366 DOI: 10.1186/s40880-016-0092-4] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 12.3] [Reference Citation Analysis]
42 Strotman LN, Millner LM, Valdes R Jr, Linder MW. Liquid Biopsies in Oncology and the Current Regulatory Landscape. Mol Diagn Ther 2016;20:429-36. [PMID: 27324559 DOI: 10.1007/s40291-016-0220-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
43 Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012;30:679-92. [PMID: 22781697 DOI: 10.1038/nbt.2284] [Cited by in Crossref: 629] [Cited by in F6Publishing: 530] [Article Influence: 62.9] [Reference Citation Analysis]
44 Cisneros-villanueva M, Hidalgo-pérez L, Rios-romero M, Cedro-tanda A, Ruiz-villavicencio CA, Page K, Hastings R, Fernandez-garcia D, Allsopp R, Fonseca-montaño MA, Jimenez-morales S, Padilla-palma V, Shaw JA, Hidalgo-miranda A. Cell-free DNA analysis in current cancer clinical trials: a review. Br J Cancer. [DOI: 10.1038/s41416-021-01696-0] [Reference Citation Analysis]
45 Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, Loguidice L, Soto H, Garrett M, Zhu LD, Sivaraman S, Chen C, Wong ET, Carter BS, Hochberg FH, Breakefield XO, Skog J. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Mol Ther Nucleic Acids 2013;2:e109. [PMID: 23881452 DOI: 10.1038/mtna.2013.28] [Cited by in Crossref: 185] [Cited by in F6Publishing: 187] [Article Influence: 20.6] [Reference Citation Analysis]
46 Ahronian LG, Corcoran RB. Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. Genome Med 2017;9:37. [PMID: 28431544 DOI: 10.1186/s13073-017-0431-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 7.4] [Reference Citation Analysis]
47 Wei Z, Wang W, Shu Z, Zhou X, Zhang Y. Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer. Med Sci Monit 2017;23:3627-34. [PMID: 28742791 DOI: 10.12659/msm.902265] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
48 Chu D, Paoletti C, Gersch C, VanDenBerg DA, Zabransky DJ, Cochran RL, Wong HY, Toro PV, Cidado J, Croessmann S, Erlanger B, Cravero K, Kyker-Snowman K, Button B, Parsons HA, Dalton WB, Gillani R, Medford A, Aung K, Tokudome N, Chinnaiyan AM, Schott A, Robinson D, Jacks KS, Lauring J, Hurley PJ, Hayes DF, Rae JM, Park BH. ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. Clin Cancer Res 2016;22:993-9. [PMID: 26261103 DOI: 10.1158/1078-0432.CCR-15-0943] [Cited by in Crossref: 117] [Cited by in F6Publishing: 64] [Article Influence: 16.7] [Reference Citation Analysis]
49 Moynahan ME, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Ringeisen F, Hortobagyi GN, Baselga J, Chandarlapaty S. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2. Br J Cancer 2017;116:726-30. [PMID: 28183140 DOI: 10.1038/bjc.2017.25] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 14.4] [Reference Citation Analysis]
50 de Bruin EC, Whiteley JL, Corcoran C, Kirk PM, Fox JC, Armisen J, Lindemann JPO, Schiavon G, Ambrose HJ, Kohlmann A. Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients. PLoS One 2017;12:e0175779. [PMID: 28472036 DOI: 10.1371/journal.pone.0175779] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
51 Huang WS, Wang TB, He Y, Chen YJ, Zhong SL, Tan M. Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948. World J Gastroenterol 2012; 18(26): 3458-3464 [PMID: 22807617 DOI: 10.3748/wjg.v18.i26.3458] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
52 Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, Lee HY, Sun JM, Lee SH, Ahn JS, Cho EK, Kim DW, Kim HR, Min YJ, Jung SH, Park K, Mao M, Ahn MJ. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget 2016;7:6984-93. [PMID: 26755650 DOI: 10.18632/oncotarget.6874] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 14.8] [Reference Citation Analysis]
53 O'Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, Liu Y, Bartlett CH, Koehler M, Cristofanilli M, Garcia-Murillas I, Bliss JM, Turner NC. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun 2018;9:896. [PMID: 29497091 DOI: 10.1038/s41467-018-03215-x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 148] [Article Influence: 42.0] [Reference Citation Analysis]
54 Johnson DB, Sullivan RJ. Biomarkers in melanoma: where are we now? Melanoma Manag 2014;1:139-50. [PMID: 30190819 DOI: 10.2217/mmt.14.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, Stehr H, Liu CL, Bratman SV, Say C. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34:547-555. [PMID: 27018799 DOI: 10.1038/nbt.3520] [Cited by in Crossref: 524] [Cited by in F6Publishing: 457] [Article Influence: 87.3] [Reference Citation Analysis]
56 Wong HY, Park BH. Plasma tumor DNA: on your markers, get set, go! Ann Transl Med 2014;2:2. [PMID: 25332978 DOI: 10.3978/j.issn.2305-5839.2013.06.07] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
57 Francis G, Stein S. Circulating Cell-Free Tumour DNA in the Management of Cancer. Int J Mol Sci 2015;16:14122-42. [PMID: 26101870 DOI: 10.3390/ijms160614122] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 9.0] [Reference Citation Analysis]
58 Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015;6:12809-12821. [PMID: 25980577 DOI: 10.18632/oncotarget.3373] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 10.0] [Reference Citation Analysis]
59 Guercio BJ, Zhang S, Venook AP, Ou FS, Niedzwiecki D, Lenz HJ, Innocenti F, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Brown JC, O'Reilly EM, Mayer RJ, Blanke CD, Fuchs CS, Meyerhardt JA. Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectr 2020;4:pkaa024. [PMID: 33134818 DOI: 10.1093/jncics/pkaa024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Jelovac D, Beaver JA, Balukrishna S, Wong HY, Toro PV, Cimino-Mathews A, Argani P, Stearns V, Jacobs L, VanDenBerg D, Kessler J, Jeter S, Park BH, Wolff AC. A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers. Hum Pathol 2014;45:880-3. [PMID: 24444464 DOI: 10.1016/j.humpath.2013.10.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
61 Davidson BA, Croessmann S, Park BH. The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer. Br J Cancer 2021. [PMID: 34040179 DOI: 10.1038/s41416-021-01422-w] [Reference Citation Analysis]
62 Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol 2017;28:642-50. [PMID: 27993791 DOI: 10.1093/annonc/mdw670] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
63 Price T, Ang A, Boedigheimer M, Kim TW, Li J, Cascinu S, Ruff P, Satya Suresh A, Thomas A, Tjulandin S, Peeters M. Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biol Ther 2020;21:891-8. [PMID: 33026965 DOI: 10.1080/15384047.2020.1798695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015;16:937-48. [PMID: 26184520 DOI: 10.1016/S1470-2045(15)00138-2] [Cited by in Crossref: 209] [Cited by in F6Publishing: 117] [Article Influence: 29.9] [Reference Citation Analysis]
65 Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML. The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma. Int J Mol Sci 2018;19:E1007. [PMID: 29597259 DOI: 10.3390/ijms19041007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
66 Zeng Q, Xie L, Zhou N, Liu M, Song X. Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR. Mol Diagn Ther 2017;21:443-51. [PMID: 28247181 DOI: 10.1007/s40291-017-0269-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
67 Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A. Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer. Breast Cancer Res Treat 2017;164:627-38. [PMID: 28500398 DOI: 10.1007/s10549-017-4257-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
68 Karlovich C, Goldman JW, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel D, Soria JC, Solomon B, Camidge DR, Gadgeel S, Paweletz C, Wu L, Chien S, O'Donnell P, Matheny S, Despain D, Rolfe L, Raponi M, Allen AR, Park K, Wakelee H. Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). Clin Cancer Res 2016;22:2386-95. [PMID: 26747242 DOI: 10.1158/1078-0432.CCR-15-1260] [Cited by in Crossref: 115] [Cited by in F6Publishing: 72] [Article Influence: 19.2] [Reference Citation Analysis]
69 McEvoy AC, Calapre L, Pereira MR, Giardina T, Robinson C, Khattak MA, Meniawy TM, Pritchard AL, Hayward NK, Amanuel B, Millward M, Ziman M, Gray ES. Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget 2017;8:78890-900. [PMID: 29108273 DOI: 10.18632/oncotarget.20354] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 7.6] [Reference Citation Analysis]
70 Stadler J, Eder J, Pratscher B, Brandt S, Schneller D, Müllegger R, Vogl C, Trautinger F, Brem G, Burgstaller JP. SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients. PLoS One 2015;10:e0142273. [PMID: 26562020 DOI: 10.1371/journal.pone.0142273] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
71 Chen X, Wang L, Lou J. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review. Med Sci Monit 2020;26:e921040. [PMID: 32200389 DOI: 10.12659/MSM.921040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Shoukry M, Broccard S, Kaplan J, Gabriel E. The Emerging Role of Circulating Tumor DNA in the Management of Breast Cancer. Cancers (Basel) 2021;13:3813. [PMID: 34359713 DOI: 10.3390/cancers13153813] [Reference Citation Analysis]
73 Yang X, Zhang K, Zhang C, Peng R, Sun C. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer. BMC Cancer 2019;19:465. [PMID: 31101027 DOI: 10.1186/s12885-019-5698-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
74 Toro PV, Erlanger B, Beaver JA, Cochran RL, VanDenBerg DA, Yakim E, Cravero K, Chu D, Zabransky DJ, Wong HY, Croessmann S, Parsons H, Hurley PJ, Lauring J, Park BH. Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clin Biochem 2015;48:993-8. [PMID: 26234639 DOI: 10.1016/j.clinbiochem.2015.07.097] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 9.9] [Reference Citation Analysis]
75 Sarangi S, Mosulpuria K, Higgins MJ, Bardia A. The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: from Enumeration to Molecular Characterization. Curr Breast Cancer Rep 2014;6:146-53. [PMID: 25431637 DOI: 10.1007/s12609-014-0149-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
76 Nam KH, Kim P, Wood DK, Kwon S, Provenzano PP, Kim DH. Multiscale Cues Drive Collective Cell Migration. Sci Rep 2016;6:29749. [PMID: 27460294 DOI: 10.1038/srep29749] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
77 Polivka J Jr, Pesta M, Janku F. Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? Expert Rev Mol Diagn 2015;15:1631-44. [PMID: 26559503 DOI: 10.1586/14737159.2015.1110021] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
78 Lin J, Ma L, Zhang D, Gao J, Jin Y, Han Z, Lin D. Tumour biomarkers-Tracing the molecular function and clinical implication. Cell Prolif 2019;52:e12589. [PMID: 30873683 DOI: 10.1111/cpr.12589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
79 Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, Yang XR, Zhou J. Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity. J Cancer. 2016;7:1907-1914. [PMID: 27698932 DOI: 10.7150/jca.15823] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
80 De Mattos-Arruda L, Rodon J. Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. Oncologist 2013;18:1180-8. [PMID: 24136009 DOI: 10.1634/theoncologist.2013-0135] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
81 Zhou Y, Xu Y, Gong Y, Zhang Y, Lu Y, Wang C, Yao R, Li P, Guan Y, Wang J, Xia X, Yang L, Yi X, Sun Q. Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer. Mol Oncol 2019;13:1033-46. [PMID: 30672098 DOI: 10.1002/1878-0261.12456] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
82 Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F, Pantano F, Dell'Aquila E, Anesi C, Silvestris N, Argentiero A, Solimando AG, Vincenzi B, Tonini G, Santini D. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J Exp Clin Cancer Res 2020;39:95. [PMID: 32460897 DOI: 10.1186/s13046-020-01601-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 20.0] [Reference Citation Analysis]
83 Tellez-Gabriel M, Knutsen E, Perander M. Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies. Int J Mol Sci 2020;21:E9457. [PMID: 33322643 DOI: 10.3390/ijms21249457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
84 Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10:472-484. [PMID: 23836314 DOI: 10.1038/nrclinonc.2013.110] [Cited by in Crossref: 946] [Cited by in F6Publishing: 890] [Article Influence: 105.1] [Reference Citation Analysis]
85 Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y, Iwase H. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. Oncotarget 2016;7:32504-18. [PMID: 27102299 DOI: 10.18632/oncotarget.8839] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
86 Deng G, Krishnakumar S, Powell AA, Zhang H, Mindrinos MN, Telli ML, Davis RW, Jeffrey SS. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer 2014;14:456. [PMID: 24947048 DOI: 10.1186/1471-2407-14-456] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 9.4] [Reference Citation Analysis]
87 Kodahl AR, Ehmsen S, Pallisgaard N, Jylling AMB, Jensen JD, Laenkholm AV, Knoop AS, Ditzel HJ. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer. Mol Oncol 2018;12:925-35. [PMID: 29689598 DOI: 10.1002/1878-0261.12305] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
88 Elazezy M, Joosse SA. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J 2018;16:370-8. [PMID: 30364656 DOI: 10.1016/j.csbj.2018.10.002] [Cited by in Crossref: 116] [Cited by in F6Publishing: 111] [Article Influence: 29.0] [Reference Citation Analysis]
89 Zhou Y, Wang C, Zhu H, Lin Y, Pan B, Zhang X, Huang X, Xu Q, Xu Y, Sun Q. Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy. PLoS One 2016;11:e0158143. [PMID: 27336598 DOI: 10.1371/journal.pone.0158143] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
90 Jahangiri L, Hurst T. Assessing the Concordance of Genomic Alterations between Circulating-Free DNA and Tumour Tissue in Cancer Patients. Cancers (Basel) 2019;11:E1938. [PMID: 31817150 DOI: 10.3390/cancers11121938] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
91 Church M, Carter L, Blackhall F. Liquid Biopsy in Small Cell Lung Cancer-A Route to Improved Clinical Care? Cells 2020;9:E2586. [PMID: 33287165 DOI: 10.3390/cells9122586] [Reference Citation Analysis]
92 Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Clin Oncol 2019;37:2620-31. [PMID: 31408415 DOI: 10.1200/JCO.19.01019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 6.3] [Reference Citation Analysis]
93 Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:904-16. [PMID: 28576675 DOI: 10.1016/S1470-2045(17)30376-5] [Cited by in Crossref: 287] [Cited by in F6Publishing: 156] [Article Influence: 57.4] [Reference Citation Analysis]
94 Sung JS, Chong HY, Kwon NJ, Kim HM, Lee JW, Kim B, Lee SB, Park CW, Choi JY, Chang WJ, Choi YJ, Lee SY, Kang EJ, Park KH, Kim YH. Detection of somatic variants and EGFR mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion ampliseq cancer hotspot panel and droplet digital polymerase chain reaction. Oncotarget 2017;8:106901-12. [PMID: 29290998 DOI: 10.18632/oncotarget.22456] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
95 Rohanizadegan M. Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker. Cancer Genet 2018;228-229:159-68. [PMID: 29572011 DOI: 10.1016/j.cancergen.2018.02.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
96 Lustberg MB, Stover DG, Chalmers JJ. Implementing Liquid Biopsies in Clinical Trials: State of Affairs, Opportunities, and Challenges. Cancer J 2018;24:61-4. [PMID: 29601331 DOI: 10.1097/PPO.0000000000000309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
97 Wang M, Li J, Huang J, Luo M. The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis. Biomed Res Int 2020;2020:1598037. [PMID: 32461963 DOI: 10.1155/2020/1598037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Pritchard KI, Chia SK, Simmons C, McLeod D, Paterson A, Provencher L, Rayson D. Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer. Oncologist 2017;22:12-24. [PMID: 27864574 DOI: 10.1634/theoncologist.2016-0185] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
99 Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579-586. [PMID: 24449238 DOI: 10.1200/jco.2012.45.2011] [Cited by in Crossref: 1225] [Cited by in F6Publishing: 738] [Article Influence: 153.1] [Reference Citation Analysis]
100 Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A. Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer. Breast Cancer Res Treat 2017;164:627-38. [PMID: 28500398 DOI: 10.1007/s10549-017-4257-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
101 Dumbrava EE, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open 2021;6:100230. [PMID: 34479035 DOI: 10.1016/j.esmoop.2021.100230] [Reference Citation Analysis]
102 Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20:1698-705. [PMID: 24429876 DOI: 10.1158/1078-0432.CCR-13-2482] [Cited by in Crossref: 517] [Cited by in F6Publishing: 298] [Article Influence: 64.6] [Reference Citation Analysis]
103 Wang R, Li X, Zhang H, Wang K, He J. Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker. Oncotarget 2017;8:75742-55. [PMID: 29088906 DOI: 10.18632/oncotarget.20608] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
104 Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol 2018;36:543-53. [PMID: 29298117 DOI: 10.1200/JCO.2017.76.0033] [Cited by in Crossref: 91] [Cited by in F6Publishing: 61] [Article Influence: 22.8] [Reference Citation Analysis]
105 Ambady P, Bettegowda C, Holdhoff M. Emerging methods for disease monitoring in malignant gliomas. CNS Oncol 2013;2:511-22. [PMID: 25054821 DOI: 10.2217/cns.13.44] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
106 Bignucolo A, De Mattia E, Cecchin E, Roncato R, Toffoli G. Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. Int J Mol Sci 2017;18:E1522. [PMID: 28708103 DOI: 10.3390/ijms18071522] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
107 Dirican E, Akkiprik M, Özer A. Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer. Tumour Biol 2016;37:7033-45. [PMID: 26921096 DOI: 10.1007/s13277-016-4924-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
108 Bonner ER, Bornhorst M, Packer RJ, Nazarian J. Liquid biopsy for pediatric central nervous system tumors. NPJ Precis Oncol 2018;2:29. [PMID: 30588509 DOI: 10.1038/s41698-018-0072-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
109 Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Mol Cancer Ther 2019;18:1149-57. [PMID: 31015311 DOI: 10.1158/1535-7163.MCT-18-1244] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
110 Han X, Wang J, Sun Y. Circulating Tumor DNA as Biomarkers for Cancer Detection. Genomics Proteomics Bioinformatics 2017;15:59-72. [PMID: 28392479 DOI: 10.1016/j.gpb.2016.12.004] [Cited by in Crossref: 113] [Cited by in F6Publishing: 101] [Article Influence: 22.6] [Reference Citation Analysis]
111 Hench IB, Hench J, Tolnay M. Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer. Front Med (Lausanne). 2018;5:9. [PMID: 29441349 DOI: 10.3389/fmed.2018.00009] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 15.3] [Reference Citation Analysis]
112 De Mattos-Arruda L, Caldas C. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. Mol Oncol. 2016;10:464-474. [PMID: 26776681 DOI: 10.1016/j.molonc.2015.12.001] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 9.6] [Reference Citation Analysis]
113 Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava-Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, Yap TA, Banerji U, Gasi Tandefelt D, Turner N, Attard G, de Bono JS. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res. 2015;21:4586-4596. [PMID: 26085511 DOI: 10.1158/1078-0432.ccr-15-0584] [Cited by in Crossref: 136] [Cited by in F6Publishing: 83] [Article Influence: 19.4] [Reference Citation Analysis]
114 Figueroa-Magalhães MC, Jelovac D, Connolly R, Wolff AC. Treatment of HER2-positive breast cancer. Breast 2014;23:128-36. [PMID: 24360619 DOI: 10.1016/j.breast.2013.11.011] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 12.6] [Reference Citation Analysis]
115 Yang Y, Shen X, Li R, Shen J, Zhang H, Yu L, Liu B, Wang L. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC. Oncotarget 2017;8:49773-82. [PMID: 28572536 DOI: 10.18632/oncotarget.17937] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
116 Borkowska EM, Barańska M, Kowalczyk M, Pietruszewska W. Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR. Biomolecules 2021;11:818. [PMID: 34072735 DOI: 10.3390/biom11060818] [Reference Citation Analysis]
117 Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Target Oncol 2017;12:97-109. [PMID: 27975152 DOI: 10.1007/s11523-016-0469-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]